Recent Quotes

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and indications in neuroscience and hematology-oncology. Jazz's product portfolio includes its lead drug, Xyrem, for narcolepsy, Sunosi for improving wakefulness in patients with excessive daytime sleepiness, Defitelio for severe veno-occlusive disease after stem cell transplant, Vyxeos for acute myeloid leukemia, and Zepzelca for small cell lung cancer.

Earnings

Q2 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-08-03
REV		(EXPECTED)2021-08-03

Q1 2021		Est.		Actual		Surprise
EPS		3.740		3.920		0.1800
REV		611.490M		607.581M		-3.909M

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Related Companies

Ticker	Company	Price	Change	Chg %		Mkt Cap
JAZZ	Jazz Pharmaceuticals	170.59	0.00	0%		10.4B

Jazz Pharmaceuticals Frequently Asked Questions

How do I buy Jazz Pharmaceuticals (JAZZ) stock?

You can purchase shares of Jazz Pharmaceuticals (NASDAQ: JAZZ) through any online brokerage.

View our list of the best stock brokerages.

Who are Jazz Pharmaceuticals's (JAZZ) competitors?

Other companies in Jazz Pharmaceuticals’s space includes: Novo Nordisk (NYSE:NVO), Reata Pharmaceuticals (NASDAQ:RETA), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK) and Novartis (NYSE:NVS).

What is the target price for Jazz Pharmaceuticals (JAZZ) stock?

The latest price target for Jazz Pharmaceuticals (NASDAQ: JAZZ) was reported by Barclays on June 22, 2021. The analyst firm set a price target for 250.00 expecting JAZZ to rise to within 12 months (a possible 46.55% upside). 19 analyst firms have reported ratings in the last year.

Current Stock Price for Jazz Pharmaceuticals (JAZZ)?

The stock price for Jazz Pharmaceuticals (NASDAQ: JAZZ) is $170.59 last updated Thu Jul 29 2021 20:00:02 GMT+0000 (Coordinated Universal Time).

Does Jazz Pharmaceuticals (JAZZ) pay a dividend?

There are no upcoming dividends for Jazz Pharmaceuticals.

When is Jazz Pharmaceuticals (NASDAQ:JAZZ) reporting earnings?

Jazz Pharmaceuticals’s Q2 earnings are confirmed for after-market on August 3, 2021.

Is Jazz Pharmaceuticals (JAZZ) going to split?

There is no upcoming split for Jazz Pharmaceuticals.

What sector and industry does Jazz Pharmaceuticals (JAZZ) operate in?

Jazz Pharmaceuticals is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.